骨髓增生异常综合征:2023年诊断、风险分层和管理更新
骨髓增生异常综合征(MDS)是一组异质性髓系肿瘤,表现为外周血细胞减少和向急性髓系白血病(AML)转化风险增加。诊断基于骨髓涂片和活检的形态学发育异常证据,2022年WHO分类将MDS更名为骨髓增生异常性肿瘤。风险分层常用IPSS-R,新近纳入基因组数据的IPSS-M。治疗根据风险、输血需求、骨髓原始细胞比例、细胞遗传学和突变特征、合并症、异基因干细胞移植(alloSCT)可能性和既往低甲基化药物(HMA)暴露选择;低危目标为减少输血需求和向高危疾病或AML转化并改善生存,高危目标为延长生存。2020年美国批准luspatercept和口服地西他滨/西达尿苷用于MDS,其他可用疗法包括生长因子、来那度胺、HMA、强化化疗和alloSCT;目前对进展或难治尤其HMA治疗失败后患者尚无获批干预。2021年多份报告提示alloSCT在MDS中改善结局,以及靶向干预临床试验的早期结果。
要点
- MDS诊断基于骨髓涂片和活检的形态学发育异常证据,核型、流式细胞术和分子遗传学通常互补并可能帮助细化诊断。
- 2022年WHO分类将MDS更名为骨髓增生异常性肿瘤。
- 风险分层常用IPSS-R,新近纳入基因组数据形成IPSS-M。
核心结论
- MDS是一组异质性髓系肿瘤,表现为外周血细胞减少和向AML转化风险增加,多见于老年男性和既往暴露于细胞毒治疗者。
- 诊断基于骨髓涂片和活检的形态学发育异常证据,核型、流式细胞术和分子遗传学通常互补并可能帮助细化诊断。
- 2022年WHO分类将MDS更名为骨髓增生异常性肿瘤。
- 风险分层常用IPSS-R,新近纳入基因组数据形成IPSS-M。
- 治疗根据风险、输血需求、骨髓原始细胞比例、细胞遗传学和突变特征、合并症、alloSCT可能性和既往HMA暴露选择;低危目标为减少输血需求和向高危疾病或AML转化并改善生存,高危目标为延长生存。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy.
- 2020年美国批准luspatercept和口服地西他滨/西达尿苷用于MDS患者。
- 目前其他可用疗法包括生长因子、来那度胺、HMA、强化化疗和alloSCT。
- 目前对进展或难治尤其HMA治疗失败后患者尚无获批干预。
- 2021年多份报告提示alloSCT在MDS中改善结局,以及靶向干预临床试验的早期结果。
关键数值与推荐
- IPSS-R为最常接受的风险分层系统,纳入外周血细胞减少、骨髓原始细胞百分比和细胞遗传学特征。
- 新近纳入基因组数据形成IPSS-M分类。
- 2022年WHO分类将MDS更名为骨髓增生异常性肿瘤。
临床怎么用
- 治疗根据风险、输血需求、骨髓原始细胞比例、细胞遗传学和突变特征、合并症、alloSCT可能性和既往HMA暴露选择。
- 低危患者目标为减少输血需求和向高危疾病或AML转化并改善生存。
- 高危患者目标为延长生存。
- 2020年美国批准luspatercept和口服地西他滨/西达尿苷用于MDS患者;其他可用疗法包括生长因子、来那度胺、HMA、强化化疗和alloSCT。
- 目前对进展或难治尤其HMA治疗失败后患者尚无获批干预。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy. DIAGNOSIS: Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry, and molecular genetics is usually complementary and may help refine diagnosis. A new WHO classification of MDS was proposed in 2022. Under this classification, MDS is now termed myelodysplastic neoplasms. RISK-STRATIFICATION: Prognosis of patients with MDS can be calculated using a number of scoring systems. All these scoring systems include analysis of peripheral cytopenias, percentage of blasts in the bone marrow, and cytogenetic characteristics. The most commonly accepted system is the Revised International Prognostic Scoring System (IPSS-R). Recently, genomic data has been incorporated resulting in the new IPSS-M classification. RISK-ADAPTED THERAPY: Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts, cytogenetic and mutational profiles, comorbidities, potential for allogeneic stem cell transplantation (alloSCT), and prior exposure to hypomethylating agents (HMA). Goals of therapy are different in lower risk patients than in higher risk and in those with HMA failure. In lower risk, the goal is to decrease transfusion needs and transformation to higher risk disease or AML, as well as to improve survival. In higher risk, the goal is to prolong survival. In 2020, two agents were approved in the US for patients with MDS: luspatercept and oral decitabine/cedazuridine. In addition, currently other available therapies include growth factors, lenalidomide, HMAs, intensive chemotherapy, and alloSCT. A number of phase 3 combinations studies have been completed or are ongoing at the time of this report. At the present time there are no approved interventions for patients with progressive or refractory disease particularly after HMA based therapy. In 2021, several reports indicated improved outcomes with alloSCT in MDS as well as early results from clinical trials using targeted intervention.
引用
- Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023. PMID: 37288607. doi:10.1002/ajh.26984
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。